Compare Amgen, Inc. (AMGN) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.78. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | HYG | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $81.32 |
52-Week Low | $271.18 | $78.72 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HYG (iShares iBoxx High Yield Corporate Bond ETF) trades at $79.71, down 0.05% with a bearish technical signal from moving averages. The ETF faces pressure from elevated put volume and broader bond market uncertainty as investors weigh potential Federal Reserve rate hikes. Recent dividend payments of $0.37-$0.42 per share provide income support, but technical indicators show weak momentum with RSI readings in neutral territory.
High-yield bond ETFs face headwinds from rising rate expectations and inflation concerns, though demand for yield remains strong. The bearish technical setup suggests near-term pressure, while institutional bearish positioning indicates cautious sentiment. Income-focused investors may find value in the dividend yield, but rate sensitivity remains a key risk factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
